JP Morgan Chase’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-20,875
| Closed | -$26.5K | – | 8089 |
|
|
2023
Q3 | $26.5K | Buy |
20,875
+11,403
| +120% | +$9.96K | ﹤0.01% | 5994 |
|
|
2023
Q2 | $3.09K | Buy |
9,472
+5,733
| +153% | +$2.06K | ﹤0.01% | 6273 |
|
|
2023
Q1 | $2K | Buy |
3,739
+3,227
| +630% | +$1.7K | ﹤0.01% | 6461 |
|
|
2022
Q4 | $0 | Buy |
512
+451
| +739% | +$286 | ﹤0.01% | 7190 |
|
|
2022
Q3 | $0 | Hold |
61
| – | – | ﹤0.01% | 7013 |
|
|
2022
Q2 | $0 | Hold |
61
| – | – | ﹤0.01% | 7050 |
|
|
2022
Q1 | $0 | Hold |
61
| – | – | ﹤0.01% | 7160 |
|
|
2021
Q4 | $0 | Hold |
61
| – | – | ﹤0.01% | 7091 |
|
|
2021
Q3 | $0 | Sell |
61
-211,944
| -100% | -$945K | ﹤0.01% | 6933 |
|
|
2021
Q2 | $1.12M | Buy |
212,005
+36,573
| +21% | +$176K | ﹤0.01% | 4208 |
|
|
2021
Q1 | $815K | Sell |
175,432
-53,569
| -23% | -$243K | ﹤0.01% | 4380 |
|
|
2020
Q4 | $755K | Buy |
229,001
+16,919
| +8% | +$64.2K | ﹤0.01% | 4128 |
|
|
2020
Q3 | $701K | Sell |
212,082
-69,620
| -25% | -$256K | ﹤0.01% | 3830 |
|
|
2020
Q2 | $950K | Sell |
281,702
-3,543
| -1% | -$16.8K | ﹤0.01% | 3545 |
|
|
2020
Q1 | $1.09M | Sell |
285,245
-47,239
| -14% | -$219K | ﹤0.01% | 3341 |
|
|
2019
Q4 | $2.01M | Sell |
332,484
-37,355
| -10% | -$255K | ﹤0.01% | 3383 |
|
|
2019
Q3 | $2.8M | Buy |
369,839
+223,072
| +152% | +$2.51M | ﹤0.01% | 3188 |
|
|
2019
Q2 | $1.86M | Buy |
+146,767
| New | +$1.69M | ﹤0.01% | 3431 |
|
|
2019
Q1 | – | Sell |
-143,608
| Closed | -$427K | – | 6120 |
|
|
2018
Q4 | $427K | Buy |
+143,608
| New | +$786K | ﹤0.01% | 4215 |
|
|
2018
Q2 | – | Sell |
-12,217
| Closed | -$106K | – | 5744 |
|
|
2018
Q1 | $106K | Buy |
12,217
+9,701
| +386% | +$105K | ﹤0.01% | 4573 |
|
|
2017
Q4 | $32K | Buy |
2,516
+2,016
| +403% | +$23.1K | ﹤0.01% | 5045 |
|
|
2017
Q3 | $5K | Sell |
500
-325,950
| -100% | -$3.45M | ﹤0.01% | 4800 |
|
|
2017
Q2 | $5.54M | Buy |
326,450
+325,950
| +65,190% | +$6.48M | ﹤0.01% | 2408 |
|
|
2017
Q1 | $10K | Buy |
+500
| New | +$9.94K | ﹤0.01% | 4820 |
|
|
2016
Q2 | – | Sell |
-174,900
| Closed | -$1.65M | – | 5019 |
|
|
2016
Q1 | $1.65M | Sell |
174,900
-5,100
| -3% | -$41.1K | ﹤0.01% | 2799 |
|
|
2015
Q4 | $1.81M | Buy |
+180,000
| New | +$2.38M | ﹤0.01% | 2802 |
|
JP Morgan Chase's ZYNE Position: Q4 2023 in Review
JP Morgan Chase sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 20,875 shares — an estimated $26.5K sold.
JP Morgan Chase first reported a position in ZYNE in Q4 2015 and held it in 26 quarters. The position peaked at $5.54M in Q2 2017. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- JP Morgan Chase reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- JP Morgan Chase sold 20,875 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $26.5K.
- JP Morgan Chase first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2015 and held it in 26 quarters.
- JP Morgan Chase's Zynerba Pharmaceuticals, Inc position peaked at $5.54M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.